The Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals' CPI-613 in Combination with Modified FOLFIRINOX in Patients with Metastatic Pancreatic Cancer; Promising Efficacy S

Press/Media: Press / Media

PeriodMay 9 2017

Media coverage

1

Media coverage

  • TitleThe Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals' CPI-613 in Combination with Modified FOLFIRINOX in Patients with Metastatic Pancreatic Cancer; Promising Efficacy S
    Media name/outletPrimeNewswire (Top News)
    CountryUnited States
    Date5/9/17
    PersonsAngela Alistar